Pfizer and BioNTech launch study to evaluate omicron-based COVID-19 vaccine for adults 18 to 55 years old
Yahoo! Finance
Pfizer Inc. and German partner BioNTech SE said Tuesday they are launching a trial to evaluate an omicron-based COVID-19 vaccine in healthy adults aged 18 to 55. "While current research and real-world data show that boosters continue to provide a high level of protection against severe disease and hospitalization with Omicron, we recognize the need to be prepared in the event this protection wanes over time and to potentially help address Omicron and new variants in the future," said Kathrin U.
Continue Reading